Form 4: Lexicon Pharmaceuticals Director Samuel Barker Reports Stock Transactions
SEC Form 4 Filing
Director Samuel Barker reports acquisition and disposal of Lexicon Pharmaceuticals common stock and restricted stock units on May 13, 2025.
Summary
- On May 13, 2025, Samuel L. Barker, a director of Lexicon Pharmaceuticals, reported transactions involving the company's stock.
- Barker acquired 36,810 shares of common stock at a price of $0.
- He also disposed of 36,810 restricted stock units.
- Following these transactions, Barker beneficially owns 124,459 shares of Lexicon Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the trading activities of key personnel.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider trading activity.
- It helps maintain investor confidence by ensuring compliance with securities regulations.
Key Dates
| Date | Description |
|---|---|
| 05/13/2025 | Date of earliest transaction and filing date. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, LXRX, Lexicon Pharmaceuticals, Samuel Barker, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.